SCHEMBL2605170

SCHEMBL2605170

CC(C)(C)c1ccc2occc2c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPM2A O95278 1/20 0.53
PTPRC P08575 1/20 0.53
PTPN6 P29350 1/20 0.53
CDC14A Q9UNH5 1/20 0.53
PTPN22 Q9Y2R2 1/20 0.53
CYP2A6 P11509 2/20 0.46
DYRK1A Q13627 6/20 0.43
CDK9 P50750 1/20 0.42
HTR1B P28222 5/20 0.41
CTNNB1 P35222 3/20 0.39
WNT3A P56704 3/20 0.39
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL29028842 0.96 EPM2A (0.50) EPM2APTPRCPTPN6CDC14APTPN22
Aniline SCHEMBL29183835 0.87 EPM2A (0.47) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL18501701 0.85 DYRK1A (0.59) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL1492819 0.84 EPM2A (0.50) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL2609996 0.83 HTR1B (0.41) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL12761344 0.82 EPM2A (0.49) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL1602098 0.80 EPM2A (0.50) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL827855 0.79 EPM2A (0.62) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL31292430 0.78 EPM2A (0.53) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL31280683 0.78 ESR1 (0.53) EPM2APTPRCPTPN6CDC14APTPN22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 WO disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-118265429-A Organic light-emitting element 吉林省元合电子材料有限公司 2024-06-28 CN disclosed
CN-114478601-B Condensed ring compound containing boron atom, nitrogen atom and selenium atom or tellurium atom, and organic electroluminescent device 中国科学院长春应用化学研究所 2024-03-29 CN disclosed
US-20240067673-A1 MODIFIED NUCLEOSIDE OR NUCLEOTIDE BGI SHENZHEN (CN) 2024-02-29 US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORPORATION (JP) 2007-09-13 US disclosed
US-20070191409-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds ROSKAMP RESEARCH LLC 2007-08-16 US disclosed
US-20070185130-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds ROSKAMP RESEARCH LLC 2007-08-09 US disclosed
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-07-12 US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed
US-20070105852-A1 Thiophene and furan compounds ELI LILLY AND COMPANY 2007-05-10 US disclosed
US-20070060588-A1 Fused bicycloheterocycle substituted quinuclidine derivatives ABBOTT LABORATORIES 2007-03-15 US disclosed
US-20070037855-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds ALZHEIMER'S INSTITUTE OF AMERICA, INC. 2007-02-15 US disclosed
US-20060052509-A1 Composition containing carbon nanotubes having coating thereof and process for producing them MITSUBISHI RAYON CO., LTD. (JP) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 EPM2A 3740/4885PTPRC 3598/4885PTPN6 4724/4885
US-20070060588-A1 Fused bicycloheterocycle substituted quinuclidine derivatives CHRNA1, CHRNA7, CHRNA2 EPM2A 3540/4885PTPRC 4157/4885PTPN6 4563/4885
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 EPM2A 3740/4885PTPRC 3598/4885PTPN6 4724/4885
US-20070191409-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds APP, PSEN1, PSEN2 EPM2A 407/4885PTPRC 849/4885PTPN6 4431/4885
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B EPM2A 1224/4885PTPRC 3308/4885PTPN6 2064/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B EPM2A 1224/4885PTPRC 3308/4885PTPN6 2064/4885
US-20070185130-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds APP, PSEN1, PSEN2 EPM2A 407/4885PTPRC 849/4885PTPN6 4431/4885
US-20070037855-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds APP, PSEN1, PSEN2 EPM2A 407/4885PTPRC 849/4885PTPN6 4431/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B EPM2A 3181/4885PTPRC 2082/4885PTPN6 1641/4885
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 EPM2A 2244/4885PTPRC 3991/4885PTPN6 2970/4885
US-20070105852-A1 Thiophene and furan compounds PSEN2, PSEN1, TPMT EPM2A 2903/4885PTPRC 619/4885PTPN6 1058/4885
US-20240067673-A1 MODIFIED NUCLEOSIDE OR NUCLEOTIDE NT5C3B, NT5E, NT5C2 EPM2A 4338/4885PTPRC 2210/4885PTPN6 2434/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 EPM2A 1554/4885PTPRC 2608/4885PTPN6 1977/4885
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 EPM2A 3819/4885PTPRC 3292/4885PTPN6 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.